PCSK9 inhibition for acute arterial events: more than LDL lowering
Eur Heart J
.
2021 Dec 14;42(47):4830-4832.
doi: 10.1093/eurheartj/ehab739.
Author
Carl E Orringer
1
Affiliation
1
Department of Internal Medicine, Division of Cardiovascular Disease, University of Miami Miller School of Medicine, Miami, FL, USA.
PMID:
34695198
DOI:
10.1093/eurheartj/ehab739
No abstract available
Publication types
Editorial
Comment
MeSH terms
Anticholesteremic Agents* / therapeutic use
Cholesterol, LDL
Humans
Proprotein Convertase 9*
Substances
Anticholesteremic Agents
Cholesterol, LDL
PCSK9 protein, human
Proprotein Convertase 9